Fenwick & West represented Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (CNS) disorders, in the expansion of their collaboration agreement with the Gene Therapy Program (GTP) at the University of Pennsylvania (UPenn).
The expanded agreement includes an additional five programs and extends Passage Bio’s period to exercise new programs for an additional three years (through 2025). Additionally, Passage Bio will fund discovery research at GTP and will receive exclusive rights, subject to certain limitations, to technologies resulting from the discovery program for Passage Bio products developed with GTP, such as novel capsids, toxicity reduction technologies and delivery and formulation improvements. More information about the collaboration can be obtained through Passage Bio’s announcement.
Fenwick life sciences partner Stefano Quintini and Passage’s general counsel Chip Cale worked on the transaction, with assistance from patent partner Daniel Becker.